CONGRESS PRESIDENT:
McMaster U.Prof. of Medicine (Thrombosis service) Sam SCHULMAN MD (Stockholm Karolinska Institute 1977) FRCPC (Int.Med + Haematology 2004).
7,500 attendees.
For Community physicians major advance is use of DIRECT INHIBITORS OF ACTIVATED FACTOR X for acute & extended duration treatment for Pulmonary embolism ,Deep vein thrombosis.+ Atrial fibrillation.
HISTORY( Wikipedia)
Spellman GG Jr., HL Nossel (April 1971). "Anticoagulant activity of dog hookworm." Am J Physiology 222:922-927.
A naturally occurring inhibitor of factor Xa was first reported in
1971 by Spellman et al. from the dog hookworm. In 1987, Tuszynski et al.
discovered antistasin, which was isolated from the extracts of Mexican leech, Haementeria officinalis. Soon after this, another naturally occurring inhibitor, tick anticoagulant peptide (TAP) was isolated from the extract of tick Ornithodoros moubata.[7]
APIXABAN( ELIQUIS) Pfizer & Bristol-Myers Squibb
EDOXABAN ( SAVAYSA) Daiichi Sankyo
RIVAROXABAN( XARELTO) Bayer.
FREE USA WEB SITE:
WWW.THROMBOSIS.TV
OTHER FREE USA SITES
HEMONC.TV
ONCOLOGY.TV
PAH.TV
IMPACTID.TV
HAEMOPHILIA A can be treated with PROPHYLACTIC INFUSIONS OF RECOMBINANT FACTOR VIII . REDUCES JOINT DAMAGE.. CAN COST UP TO $1-MILLION / YEAR.
22 Jun 2015
21 Jun 2015
GLOBE & MAIL .March 19. Can$10-million to found Tor Western Hosp DONALD K JOHNSON EYE CENTRE
Mr.D.K.JOHNSON .(born 1935) B.Sc(Elect.Eng. Manitoba 1957) MBA(Ivey 1963) OC LLD Member Advisory Board BMO Capital Markets.
Mrs. Anna McCowan-JOHNSON Founder of INTERPLAY BALLET SCHOOLS (.sold in 2009)
Mrs. Anna McCowan-JOHNSON Founder of INTERPLAY BALLET SCHOOLS (.sold in 2009)
GLOBE & MAIL Friday June 19 McGILL Med.Students complain about new curriculum.
Med.students' soc Pres Ms DOULIA HAMAD & Past Pres. Mr.Nebras WARSI complained about new curriculum being too hard with not enough supervision. .Also not enough about Womens' Heath, Domestic violence.& ":gender equity". Result McGill on "probation" for two years by USA LIASON COMM. ON MEDICAL EDUCTION..
18 Jun 2015
Toronto & Hollywood.(USA). Lease advisors for Dentists & Doctors CIRRUS CONSULTING GROUP.(1994)
Toronto: 20 Eglinton Av. West, # 1800
Manager Justin DITKOFSKY
jditkofsky@cirrusconsultinggroup.com
www.cirrusconsultinggroup.com
Lessors`are often economical with the truth.
Leases should protect the lessee in case of forced relocation, catastrophic illness and Estate in case of death.
Start negotiations TWO YEARS before end of lease
Always pay rent ion time. even one day late causes lessee to be in legal DEFAULT. Pay by automatic monthly bank transfer..
Best deals on long lease of 10 years plus two options of five years.
Lessor may be friendly but the lessor is NEVER YOUR FRIEND.
Every word of a lease must be read, understood and negotiated to the advantage of the lessee.
The is no STANDARD lease.
Manager Justin DITKOFSKY
jditkofsky@cirrusconsultinggroup.com
www.cirrusconsultinggroup.com
Lessors`are often economical with the truth.
Leases should protect the lessee in case of forced relocation, catastrophic illness and Estate in case of death.
Start negotiations TWO YEARS before end of lease
Always pay rent ion time. even one day late causes lessee to be in legal DEFAULT. Pay by automatic monthly bank transfer..
Best deals on long lease of 10 years plus two options of five years.
Lessor may be friendly but the lessor is NEVER YOUR FRIEND.
Every word of a lease must be read, understood and negotiated to the advantage of the lessee.
The is no STANDARD lease.
15 Jun 2015
TORONTO PARAPAN-AMERICAN GAMES: Dr.H.L.FRANKEL OBE FRCPC was Physician Advisor to Neurosurgeon Sir..L.GUTTMANN KBE FRS
Dr Hans Ludwig Frankel, OBE, MB, FRCP
Guttmann Lecturer 2012
Few are more qualified to honour Sir Ludwig Guttmann than Dr Hans Ludwig Frankel, his understudy and colleague for more than 22 years, 1958-1980 (Guttmann’s death)). Dr Frankel was called on frequently over the years to pay tribute to his Mentor. On the occasion of Dr Guttmann’s 70th birthday, Dr Frankel was asked and delivered his famous paper defining the Frankel Grades (Frankel 1969), the most frequently cited outcome measure for the study of spinal cord injury in the literature today (Ditunno 2010). Dr Frankel was one of the successors to Sir Ludwig at Stoke Mandeville Hospital and continued the tradition of dedicated care, learning and research at this institution so dear to its Founder. Dr Frankel has also continued Sir Ludwig’s work at the British Paraplegic Sports Society (now WheelPower), IMSoP (now ISCoS) and the journal Paraplegia (now Spinal Cord), all founded by Guttmann.
Who other than Hans Frankel could have described his Mentor with such profound respect as on the occasion of his “100th Birthday” in 1999?
“Those who never met Guttmann wonder how he achieved so much. He was a small man of immense energy and when he became animated he seemed to grow in size and almost filled the room. He was both loved and feared and inspired great loyalty in his followers.”
John F Ditunno, Jr. MD
Professor of Rehabilitation Medicine, Jefferson Medical College
Philadelphia, USA
10 Jun 2015
JUNE 19 (Fri) MULTIPLE MYELOMA(Plasma cell cancer) Toronto VAUGHAN ESTATE SUNNYBROOK HOSP SCOTTSDALE MAYO CLINIC Prof Keith STEWART
Princess Margaret Cancer Centre and the Department of Medicine, University of Toronto
FOR INFORMATION
Continuing Professional Development
Faculty of Medicine, University of Toronto
416.978.2719 | 1.888.512.8173 | info-MED1507@cpdtoronto.ca
www.cpd.utoronto.ca/myeloma
Keith Stewart, M.B., Ch.B.(Aberdeen) FRCP(Can) MBA(Ivey)
SUMMARY
Keith Stewart, M.B., Ch.B., conducts translational research in multiple myeloma. This includes both basic and clinical research to identify novel targets for therapy in multiple myeloma.Dr. Stewart's research is supported by the National Cancer Institute, Multiple Myeloma Research Foundation, and Leukemia & Lymphoma Society, as well as by partnerships with the pharmaceutical industry for clinical trials.
Focus areas
Dr. Stewart's research can be divided into three broad categories:- Study of the cancer genome. Recently, Dr. Stewart and his colleagues have focused on the use of high-throughput druggable genome RNAi screening in the presence or absence of therapeutic agents such as bortezomib and lenalidomide. This work will lead to the identification of targets that, when suppressed, sensitize myeloma cells to the effects of chemotherapy. Most recently, they have also begun whole-genome sequencing of myeloma cells in patients who have become resistant to chemotherapy drugs in an attempt to identify mechanisms of resistance. Their first whole human genome sequence was completed in June 2009.
- Cancer drug development. Dr. Stewart and his team have performed high-throughput screens of small molecules to identify inhibitors of myeloma targets. With these screens, they have been successful in identifying a number of small molecules that resulted in cell death when applied to myeloma cells. They have employed a medicinal chemistry approach to the development of analogues for these molecules and will pursue these into preclinical testing and subsequently into clinical trials.
- Clinical trials. These include early investigational phase I studies and large international randomized phase III trials. Novel agents being studied include carfilzomib, pomalidomide, aurora kinase, heat shock protein 90, CDK5 and FGFR3 inhibitors.
Significance to patient care
Dr. Stewart and his colleagues are conducting research that has direct relevance to patient care, as they are discovering markers for prognosis and drug responsiveness, understanding what makes patients resistant to drugs, and applying this knowledge in the clinic with clinical trials exploring novel therapeutics in multiple myeloma, amyloidosis and other blood cancers.Treatment of relapsed multiple myeloma.
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. [N Engl J Med. 2015]
UK DAILY MAIL: PRIVATE SUITE @ MASS GENERAL
On the mend: The photo shows Kerry in
his room at Massachusetts General Hospital in Boston. He has his right
leg propped up and is talking on the phone with national security
adviser Susan Rice
Subscribe to:
Posts (Atom)